Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.

ABSTRACT:

Objectives

Colchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reducing Intereukin-6, Interleukin-8, Tumour Necrosis Factor-alpha besides controlling oxidative stress pathways which all are important and pathologic components in the clinical course and outcome of patients infected with COVID-19. This study aims to assess the anti-inflammatory effects of colchicine in non-severe hospitalized COVID-19 patients.

Trial design

Prospective, randomized (1:1 ratio), double blind study with parallel group design.

Participants

Hospitalized patients with positive nasopharyngeal swab for COVID-19 infection (RT -PCR) and lung Compu

SUBMITTER: Dalili N 

PROVIDER: S-EPMC7273823 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature